Enanthema as the first clinical manifestation of abacavir hypersensitivity reaction: a case report.
Abacavir is a nucleoside analogue reverse transcriptase inhibitor used in combination with other antiretroviral drugs for the treatment of HIV 1-infection. Approximately 3% of patients who receive abacavir develop an idiosyncratic hypersensitivity reaction. The most common symptoms are fever, skin rash and gastrointestinal disorders. Respiratory symptoms occurred in approximately 20% of patients who have hypersensitivity reaction. We describe the first case, to our knowledge, of hypesensitivity reaction characterized by enanthema and fever without skin rash promptly resolved after discontinuation of abacavir
Lanzafame
Massimilliano
M
Divisione Clinicizzata di Malattie Infettive, Istituto di Immunologia e Malattie Infettive, Ospedale Civile Maggiore di Borgo Trento, Verona, Italy.
Trevenzoli
Marco
M
Lattuada
Emanuela
E
Faggian
Federica
F
Vento
Sandro
S
Concia
Ercole
E
D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects*; D015224:Dideoxynucleosides / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology*; D006801:Humans; D008297:Male; D000099227:Abacavir
D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D000099227:Abacavir